Using ‘omics’ to define pathogenesis and biomarkers of Parkinson’s disease

References

• Fahn S. Description of Parkinson’s disease as a clinical syndrome. Ann. NY Acad. Sci.991, 1–14 (2003).
   PubMed Web of Science ®Google Scholar
• DeLong MR, Wichmann T. Circuits and circuit disorders of the basal ganglia. Arch. Neurol.64(1), 20–24 (2007).
   PubMedGoogle Scholar
• Ehringer H, Hornykiewicz O. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. Klin. Wochenschr.38, 1236–1239 (1960).
   PubMed Web of Science ®Google Scholar
• Jellinger K. New developments in the pathology of Parkinson’s disease. Adv. Neurol.53, 1–16 (1990).
   PubMedGoogle Scholar
• Braak H, Braak E, Yilmazer D et al. Nigral and extranigral pathology in Parkinson’s disease. J. Neural Transm. Suppl.46, 15–31 (1995).
   Google Scholar
• Forno LS. Neuropathology of Parkinson’s disease. J. Neuropathol. Exp. Neurol.55(3), 259–272 (1996).
   PubMed Web of Science ®Google Scholar
• Schlossmacher MG, Frosch MP, Gai WP et al. Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am. J. Pathol.160(5), 1655–1667 (2002).
   PubMed Web of Science ®Google Scholar
• Jenner P, Olanow CW. Understanding cell death in Parkinson’s disease. Ann. Neurol.44(3 Suppl. 1), S72–S84 (1998).
   PubMed Web of Science ®Google Scholar
• Jenner P. Oxidative stress in Parkinson’s disease. Ann. Neurol.53(Suppl. 3), S26–S36; discussion S36–S28 (2003).
   PubMed Web of Science ®Google Scholar
• Olanow CW, Tatton WG. Etiology and pathogenesis of Parkinson’s disease. Annu. Rev. Neurosci.22, 123–144 (1999).
   PubMed Web of Science ®Google Scholar
• Blandini F, Porter RH, Greenamyre JT. Glutamate and Parkinson’s disease. Mol. Neurobiol.12(1), 73–94 (1996).
   PubMed Web of Science ®Google Scholar
• Beal MF. Excitotoxicity and nitric oxide in Parkinson’s disease pathogenesis. Ann. Neurol.44(3 Suppl. 1), S110–S114 (1998).
   Web of Science ®Google Scholar
• Wersinger C, Sidhu A. An inflammatory pathomechanism for Parkinson’s disease? Curr. Med. Chem.13(5), 591–602 (2006).
   PubMed Web of Science ®Google Scholar
• Schapira AH. Mitochondrial dysfunction in neurodegenerative disorders. Biochim. Biophys. Acta1366(1–2), 225–233 (1998).
   PubMed Web of Science ®Google Scholar
• Schapira AH, Mann VM, Cooper JM et al. Mitochondrial function in Parkinson’s disease. The Royal Kings and Queens Parkinson’s Disease Research Group. Ann. Neurol.32(Suppl.), S116–S124 (1992).
   PubMed Web of Science ®Google Scholar
• Olanow CW, McNaught KS. Ubiquitin-proteasome system and Parkinson’s disease. Mov. Disord.21(11), 1806–1823 (2006).
   PubMed Web of Science ®Google Scholar
• McNaught KS, Jackson T, JnoBaptiste R, Kapustin A, Olanow CW. Proteasomal dysfunction in sporadic Parkinson’s disease. Neurology66(10 Suppl. 4), S37–S49 (2006).
   PubMedGoogle Scholar
• Petrucelli L, Dawson TM. Mechanism of neurodegenerative disease: role of the ubiquitin proteasome system. Ann. Med.36(4), 315–320 (2004).
   PubMed Web of Science ®Google Scholar
• Hirsch EC. Mechanism and consequences of nerve cell death in Parkinson’s disease. J. Neural Transm. Suppl.56, 127–137 (1999).
   PubMedGoogle Scholar
• Tatton NA, Maclean-Fraser A, Tatton WG, Perl DP, Olanow CW. A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson’s disease. Ann. Neurol.44(3 Suppl. 1), S142–S148 (1998).
   Web of Science ®Google Scholar
• Tatton NA. Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson’s disease. Exp. Neurol.166(1), 29–43 (2000).
   PubMed Web of Science ®Google Scholar
• Jellinger KA. Cell death mechanisms in neurodegeneration. J. Cell. Mol. Med.5(1), 1–17 (2001).
   PubMed Web of Science ®Google Scholar
• Farrer MJ. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat. Rev. Genet.7(4), 306–318 (2006).
   PubMed Web of Science ®Google Scholar
• Schapira AH. Etiology of Parkinson’s disease. Neurology66(10 Suppl. 4), S10–S23 (2006).
   PubMed Web of Science ®Google Scholar
• Allen W. Inheritance of the shaking palsy. Arch. Int. Med.60, 424–436 (1937).
   Google Scholar
• Leroux P-D. Contributions to the reasons and causes of shaking palsy. PhD Thesis. Imprimeur de la Faculte de Medecine, Paris, France (1880).
   Google Scholar
• Mjones H. Paralysis agitans: a clinical and genetic study. Acta. Psychiatr. Neurol. Scand.Suppl.54, 1–195 (1949).
   Google Scholar
• Tanner CM, Goldman SM. Epidemiology of Parkinson’s disease. Neurol. Clin.14(2), 317–335 (1996).
   PubMed Web of Science ®Google Scholar
• Tanner CM, Langston JW. Do environmental toxins cause Parkinson’s disease? A critical review. Neurology40(10 Suppl. 3), 17–30; discussion 30–11 (1990).
   PubMed Web of Science ®Google Scholar
• Ascherio A, Chen H, Weisskopf MG et al. Pesticide exposure and risk for Parkinson’s disease. Ann. Neurol.60(2), 197–203 (2006).
   PubMed Web of Science ®Google Scholar
• Corrigan FM, Wienburg CL, Shore RF, Daniel SE, Mann D. Organochlorine insecticides in substantia nigra in Parkinson’s disease. J. Toxicol. Environ. Health A59(4), 229–234 (2000).
   PubMed Web of Science ®Google Scholar
• Hubble JP, Cao T, Hassanein RE, Neuberger JS, Koller WC. Risk factors for Parkinson’s disease. Neurology43(9), 1693–1697 (1993).
   PubMed Web of Science ®Google Scholar
• Priyadarshi A, Khuder SA, Schaub EA, Shrivastava S. A meta-analysis of Parkinson’s disease and exposure to pesticides. Neurotoxicology21(4), 435–440 (2000).
   PubMed Web of Science ®Google Scholar
• Semchuk KM, Love EJ, Lee RG. Parkinson’s disease and exposure to rural environmental factors: a population based case–control study. Can. J. Neurol. Sci.18(3), 279–286 (1991).
   PubMed Web of Science ®Google Scholar
• Semchuk KM, Love EJ, Lee RG. Parkinson’s disease and exposure to agricultural work and pesticide chemicals. Neurology42(7), 1328–1335 (1992).
   PubMed Web of Science ®Google Scholar
• Steenland K, Hein MJ, Cassinelli RT 2nd et al. Polychlorinated biphenyls and neurodegenerative disease mortality in an occupational cohort. Epidemiology17(1), 8–13 (2006).
   PubMed Web of Science ®Google Scholar
• Fleming L, Mann JB, Bean J, Briggle T, Sanchez-Ramos JR. Parkinson’s disease and brain levels of organochlorine pesticides. Ann. Neurol.36(1), 100–103 (1994).
   PubMed Web of Science ®Google Scholar
• Ho SC, Woo J, Lee CM. Epidemiologic study of Parkinson’s disease in Hong Kong. Neurology39(10), 1314–1318 (1989).
   PubMed Web of Science ®Google Scholar
• Le Couteur DG, McLean AJ, Taylor MC, Woodham BL, Board PG. Pesticides and Parkinson’s disease. Biomed. Pharmacother.53(3), 122–130 (1999).
   PubMed Web of Science ®Google Scholar
• Norris EH, Uryu K, Leight S et al. Pesticide exposure exacerbates α-synucleinopathy in an A53T transgenic mouse model. Am. J. Pathol.170(2), 658–666 (2007).
   PubMed Web of Science ®Google Scholar
• Yang YH, Speed T. Design issues for cDNA microarray experiments. Nat. Rev.3(8), 579–588 (2002).
   Google Scholar
• Wu Z, Irizarry RA. Preprocessing of oligonucleotide array data. Nat. Biotech.22(6), 656–658; author reply 658 (2004).
   PubMedGoogle Scholar
• Sutherland GT, Matigian NA, Chalk AM et al. A cross-study transcriptional analysis of Parkinson’s disease. PLoS One,4(3), e4955 (2009).
   PubMed Web of Science ®Google Scholar
• Miller RM, Federoff HJ. Altered gene expression profiles reveal similarities and differences between Parkinson disease and model systems. Neuroscientist11(6), 539–549 (2005).
   Google Scholar
• Miller RM, Kiser GL, Kaysser-Kranich TM et al. Robust dysregulation of gene expression in substantia nigra and striatum in Parkinson’s disease. Neurobiol. Dis.21(2), 305–313 (2006).
   PubMed Web of Science ®Google Scholar
• Duke DC, Moran LB, Kalaitzakis ME et al. Transcriptome analysis reveals link between proteasomal and mitochondrial pathways in Parkinson’s disease. Neurogenetics7(3), 139–148 (2006).
   PubMed Web of Science ®Google Scholar
• Duke DC, Moran LB, Pearce RK, Graeber MB. The medial and lateral substantia nigra in Parkinson’s disease: mRNA profiles associated with higher brain tissue vulnerability. Neurogenetics8(2), 83–94 (2007).
   PubMed Web of Science ®Google Scholar
• Mandel S, Grunblatt E, Riederer P et al. Gene expression profiling of sporadic Parkinson’s disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70. Ann. NY Acad. Sci.1053, 356–375 (2005).
   PubMed Web of Science ®Google Scholar
• Grunblatt E, Mandel S, Jacob-Hirsch J et al. Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J. Neural Transm.111(12), 1543–1573 (2004).
   PubMed Web of Science ®Google Scholar
• Hauser MA, Li YJ, Xu H et al. Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism. Arch. Neurol.62(6), 917–921 (2005).
   PubMed Web of Science ®Google Scholar
• Simunovic F, Yi M, Wang Y et al. Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson’s disease pathology. Brain132(Pt 7), 1795–1809 (2009).
   PubMed Web of Science ®Google Scholar
• Przedborski S, Jackson-Lewis V, Djaldetti R et al. The parkinsonian toxin MPTP: action and mechanism. Restor. Neurol. Neurosci.16(2), 135–142 (2000).
   PubMed Web of Science ®Google Scholar
• Betarbet R, Sherer TB, MacKenzie G et al. Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat. Neurosci.3(12), 1301–1306 (2000).
   PubMed Web of Science ®Google Scholar
• Jackson-Lewis V, Jakowec M, Burke RE, Przedborski S. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration4(3), 257–269 (1995).
   PubMedGoogle Scholar
• Schapira AH. Human complex I defects in neurodegenerative diseases. Biochim. Biophys. Acta1364(2), 261–270 (1998).
   PubMed Web of Science ®Google Scholar
• Olanow CW, McNaught KS. Ubiquitin-proteasome system and Parkinson’s disease. Mov. Disord.21(11), 1806–1823 (2006).
   PubMed Web of Science ®Google Scholar
• Kitada T, Asakawa S, Hattori N et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature392(6676), 605–608 (1998).
   PubMed Web of Science ®Google Scholar
• Mata IF, Lockhart PJ, Farrer MJ. Parkin genetics: one model for Parkinson’s disease. Hum. Mol. Gen.13(Spec. No 1), R127–R133 (2004).
   PubMedGoogle Scholar
• McNaught KS, Bjorklund LM, Belizaire R et al. Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. Neuroreport13(11), 1437–1441 (2002).
   PubMedGoogle Scholar
• Galvin JE, Ginsberg SD. Expression profiling in the aging brain: a perspective. Ageing Res. Rev.4(4), 529–547 (2005).
   PubMedGoogle Scholar
• Nair-Roberts RG, Chatelain-Badie SD, Benson E et al. Stereological estimates of dopaminergic, GABAergic and glutamatergic neurons in the ventral tegmental area, substantia nigra and retrorubral field in the rat. Neuroscience152(4), 1024–1031 (2008).
   PubMed Web of Science ®Google Scholar
• Olanow CW. The pathogenesis of cell death in Parkinson’s disease – 2007. Mov. Disord.22(Suppl. 17), S335–S342 (2007).
   PubMed Web of Science ®Google Scholar
• Alexa A, Rahnenfuhrer J, Lengauer T. Improved scoring of functional groups from gene expression data by decorrelating GO graph structure. Bioinformatics (Oxford, England)22(13), 1600–1607 (2006).
   PubMed Web of Science ®Google Scholar
• Bossers K, Meerhoff G, Balesar R et al. Analysis of gene expression in Parkinson’s disease: possible involvement of neurotrophic support and axon guidance in dopaminergic cell death. Brain Pathol. (Zurich, Switzerland)19(1), 91–107 (2009).
   Google Scholar
• Lesnick TG, Papapetropoulos S, Mash DC et al. A genomic pathway approach to a complex disease: axon guidance and Parkinson disease. PLoS Gen.3(6), e98 (2007).
   PubMed Web of Science ®Google Scholar
• Lin L, Lesnick TG, Maraganore DM, Isacson O. Axon guidance and synaptic maintenance: preclinical markers for neurodegenerative disease and therapeutics. Trends Neurosci.32(3), 142–149 (2009).
   Google Scholar
• Zhang J, Goodlett DR, Montine TJ. Proteomic biomarker discovery in cerebrospinal fluid for neurodegenerative diseases. J. Alzheimers Dis.8(4), 377–386 (2005).
   PubMed Web of Science ®Google Scholar
• Scherzer CR, Eklund AC, Morse LJ et al. Molecular markers of early Parkinson’s disease based on gene expression in blood. Proc. Natl Acad. Sci. USA104(3), 955–960 (2007).
   PubMed Web of Science ®Google Scholar
• Scherzer CR, Grass JA, Liao Z et al. GATA transcription factors directly regulate the Parkinson’s disease-linked gene α-synuclein. Proc. Natl Acad. Sci. USA105(31), 10907–10912 (2008).
   PubMed Web of Science ®Google Scholar
• Klucken J, Shin Y, Masliah E, Hyman BT, McLean PJ. Hsp70 reduces α-synuclein aggregation and toxicity. J. Biol. Chem.279(24), 25497–25502 (2004).
   PubMed Web of Science ®Google Scholar
• Castensson A, Emilsson L, Preece P, Jazin EE. High-resolution quantification of specific mRNA levels in human brain autopsies and biopsies. Genome Res.10(8), 1219–1229 (2000).
   Google Scholar
• Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature422(6928), 198–207 (2003).
   PubMed Web of Science ®Google Scholar
• Pan S, Rush J, Peskind ER et al. Application of targeted quantitative proteomics analysis in human cerebrospinal fluid using a liquid chromatography matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometer (LC MALDI TOF/TOF) platform. J. Proteome Res.7(2), 720–730 (2008).
   PubMed Web of Science ®Google Scholar
• Pan S, Shi M, Jin J et al. Proteomics identification of proteins in human cortex using multidimensional separations and MALDI tandem mass spectrometer. Mol. Cell. Proteomics6(10), 1818–1823 (2007).
   Google Scholar
• Kitsou E, Pan S, Zhang J et al. Identification of proteins in human substantia nigra. Proteomics Clin. Appl.2, 776–782 (2008).
   PubMed Web of Science ®Google Scholar
• Tribl F, Gerlach M, Marcus K et al. “Subcellular proteomics” of neuromelanin granules isolated from the human brain. Mol. Cell. Proteomics4(7), 945–957 (2005).
   PubMed Web of Science ®Google Scholar
• Tribl F, Marcus K, Bringmann G et al. Proteomics of the human brain: sub-proteomes might hold the key to handle brain complexity. J. Neural Transm.113(8), 1041–1054 (2006).
   PubMed Web of Science ®Google Scholar
• Tribl F, Marcus K, Meyer HE et al. Subcellular proteomics reveals neuromelanin granules to be a lysosome-related organelle. J. Neural Transm.113(6), 741–749 (2006).
   PubMed Web of Science ®Google Scholar
• Fedorow H, Tribl F, Halliday G et al. Neuromelanin in human dopamine neurons: comparison with peripheral melanins and relevance to Parkinson’s disease. Prog. Neurobiol.75(2), 109–124 (2005).
   PubMed Web of Science ®Google Scholar
• Double KL, Rowe DB, Carew-Jones FM et al. Anti-melanin antibodies are increased in sera in Parkinson’s disease. Exp. Neurol.217(2), 297–301 (2009).
   PubMed Web of Science ®Google Scholar
• Xia Q, Liao L, Cheng D et al. Proteomic identification of novel proteins associated with Lewy bodies. Front. Biosci.13, 3850–3856 (2008).
   PubMed Web of Science ®Google Scholar
• Braak H, Del Tredici K, Rub U et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging24(2), 197–211 (2003).
   PubMed Web of Science ®Google Scholar
• Leverenz JB, Umar I, Wang Q et al. Proteomic identification of novel proteins in cortical lewy bodies. Brain Pathol. (Zurich, Switzerland)17(2), 139–145 (2007).
   PubMed Web of Science ®Google Scholar
• Basso M, Giraudo S, Corpillo D et al. Proteome analysis of human substantia nigra in Parkinson’s disease. Proteomics4(12), 3943–3952 (2004).
   PubMed Web of Science ®Google Scholar
• Jin J, Hulette C, Wang Y et al. Proteomic identification of a stress protein, mortalin/mthsp70/GRP75: relevance to Parkinson disease. Mol. Cell. Proteomics5(7), 1193–1204 (2006).
   PubMed Web of Science ®Google Scholar
• Shi M, Jin J, Wang Y et al. Mortalin: a protein associated with progression of Parkinson disease? J. Neuropathol. Exp. Neurol.67(2), 117–124 (2008).
   PubMedGoogle Scholar
• Jin J, Li GJ, Davis J et al. Identification of novel proteins associated with both α-synuclein and DJ-1. Mol. Cell. Proteomics6(5), 845–859 (2007).
   PubMed Web of Science ®Google Scholar
• Shi M, Bradner J, Bammler TK et al. Identification of glutathione S-transferase pi as a protein involved in Parkinson disease progression. Am. J. Pathol.175(1), 54–65 (2009).
   PubMed Web of Science ®Google Scholar
• Kelada SN, Stapleton PL, Farin FM et al. Glutathione S-transferase M1, T1, and P1 polymorphisms and Parkinson’s disease. Neurosci. Lett.337(1), 5–8 (2003).
   PubMed Web of Science ®Google Scholar
• Smeyne M, Boyd J, Raviie Shepherd K et al. GSTpi expression mediates dopaminergic neuron sensitivity in experimental parkinsonism. Proc. Natl Acad. Sci. USA104(6), 1977–1982 (2007).
   PubMed Web of Science ®Google Scholar
• Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson’s disease. Brain122(Pt 8), 1437–1448 (1999).
   PubMed Web of Science ®Google Scholar
• Fearnley JM, Lees AJ. Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain114(Pt 5), 2283–2301 (1991).
   PubMed Web of Science ®Google Scholar
• Pakkenberg B, Moller A, Gundersen HJ, Mouritzen Dam A, Pakkenberg H. The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson’s disease estimated with an unbiased stereological method. J. Neurol. Neurosurg. Psychiatry54(1), 30–33 (1991).
   PubMed Web of Science ®Google Scholar
• McGeer PL, Itagaki S, Akiyama H, McGeer EG. Rate of cell death in parkinsonism indicates active neuropathological process. Ann. Neurol.24(4), 574–576 (1988).
   PubMed Web of Science ®Google Scholar
• McRitchie DA, Cartwright HR, Halliday GM. Specific A10 dopaminergic nuclei in the midbrain degenerate in Parkinson’s disease. Exp. Neurol.144(1), 202–213 (1997).
   PubMedGoogle Scholar
• German DC, Dubach M, Askari S, Speciale SG, Bowden DM. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonian syndrome in Macaca fascicularis: which midbrain dopaminergic neurons are lost? Neuroscience24(1), 161–174 (1988).
   Google Scholar
• Varastet M, Riche D, Maziere M, Hantraye P. Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in Parkinson’s disease. Neuroscience63(1), 47–56 (1994).
   PubMed Web of Science ®Google Scholar
• Waters CM, Hunt SP, Jenner P, Marsden CD. An immunohistochemical study of the acute and long-term effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset. Neuroscience23(3), 1025–1039 (1987).
   Google Scholar
• German DC, Nelson EL, Liang CL et al. The neurotoxin MPTP causes degeneration of specific nucleus A8, A9 and A10 dopaminergic neurons in the mouse. Neurodegeneration5(4), 299–312 (1996).
   PubMedGoogle Scholar
• Rodriguez M, Barroso-Chinea P, Abdala P, Obeso J, Gonzalez-Hernandez T. Dopamine cell degeneration induced by intraventricular administration of 6-hydroxydopamine in the rat: similarities with cell loss in Parkinson’s disease. Exp. Neurol.169(1), 163–181 (2001).
   PubMed Web of Science ®Google Scholar
• Yamada T, McGeer PL, Baimbridge KG, McGeer EG. Relative sparing in Parkinson’s disease of substantia nigra dopamine neurons containing calbindin-D28K. Brain Res.526(2), 303–307 (1990).
   PubMed Web of Science ®Google Scholar
• Schein JC, Hunter DD, Roffler-Tarlov S. Girk2 expression in the ventral midbrain, cerebellum, and olfactory bulb and its relationship to the murine mutation weaver. Dev. Biol.204(2), 432–450 (1998).
   Web of Science ®Google Scholar
• Karschin C, Dissmann E, Stuhmer W, Karschin A. IRK(1–3) and GIRK(1–4) inwardly rectifying K+ channel mRNAs are differentially expressed in the adult rat brain. J. Neurosci.16(11), 3559–3570 (1996).
   PubMed Web of Science ®Google Scholar
• Beyer K. α-synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers. Acta Neuropathol.112(3), 237–251 (2006).
   PubMed Web of Science ®Google Scholar
• Choi J, Levey AI, Weintraub ST et al. Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson’s and Alzheimer’s diseases. J. Biol. Chem.279(13), 13256–13264 (2004).
   PubMed Web of Science ®Google Scholar
• Choi J, Rees HD, Weintraub ST et al. Oxidative modifications and aggregation of Cu,Zn-superoxide dismutase associated with Alzheimer and Parkinson diseases. J. Biol. Chem.280(12), 11648–11655 (2005).
   PubMed Web of Science ®Google Scholar
• Choi J, Sullards MC, Olzmann JA et al. Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases. J. Biol. Chem.281(16), 10816–10824 (2006).
   PubMed Web of Science ®Google Scholar
• Hagglund P, Bunkenborg J, Elortza F, Jensen ON, Roepstorff P. A new strategy for identification of N-glycosylated proteins and unambiguous assignment of their glycosylation sites using HILIC enrichment and partial deglycosylation. J. Proteome Res.3(3), 556–566 (2004).
   PubMed Web of Science ®Google Scholar
• Shimura H, Schlossmacher MG, Hattori N et al. Ubiquitination of a new form of α-synuclein by parkin from human brain: implications for Parkinson’s disease. Science (NY)293(5528), 263–269 (2001).
   PubMed Web of Science ®Google Scholar
• Farrer M, Maraganore DM, Lockhart P et al. α-synuclein gene haplotypes are associated with Parkinson’s disease. Hum. Mol. Gen.10(17), 1847–1851 (2001).
   PubMed Web of Science ®Google Scholar
• Hwang H, Zhang J, Chung KA et al. Glycoproteomics in neurodegenerative diseases. Mass Spect. Rev.29(1), 79–125 (2010).
   PubMed Web of Science ®Google Scholar
• Zecca L, Stroppolo A, Gatti A et al. The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proc. Natl Acad. Sci. USA101(26), 9843–9848 (2004).
   PubMed Web of Science ®Google Scholar
• Vigh B, Manzano e Silva MJ, Frank CL et al. The system of cerebrospinal fluid-contacting neurons. Its supposed role in the nonsynaptic signal transmission of the brain. Histol. Histopathol.19(2), 607–628 (2004).
   PubMed Web of Science ®Google Scholar
• Nilsson C, Lindvall-Axelsson M, Owman C. Neuroendocrine regulatory mechanisms in the choroid plexus-cerebrospinal fluid system. Brain Res. Brain Res. Rev.17(2), 109–138 (1992).
   PubMedGoogle Scholar
• Harrington MG, Fonteh AN, Oborina E et al. The morphology and biochemistry of nanostructures provide evidence for synthesis and signaling functions in human cerebrospinal fluid. Cerebrospinal Fluid Res.6, 10 (2009).
   PubMedGoogle Scholar
• Abdi F, Quinn JF, Jankovic J et al. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J. Alzheimers Dis.9(3), 293–348 (2006).
   PubMed Web of Science ®Google Scholar
• Pan S, Zhu D, Quinn JF et al. A combined dataset of human cerebrospinal fluid proteins identified by multi-dimensional chromatography and tandem mass spectrometry. Proteomics7(3), 469–473 (2007).
   PubMed Web of Science ®Google Scholar
• Johnstone RM, Adam M, Hammond JR, Orr L, Turbide C. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). J. Biol. Chem.262(19), 9412–9420 (1987).
   PubMed Web of Science ®Google Scholar
• Thery C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat. Rev. Immunol.2(8), 569–579 (2002).
   PubMed Web of Science ®Google Scholar
• Ecroyd H, Sarradin P, Dacheux JL, Gatti JL. Compartmentalization of prion isoforms within the reproductive tract of the ram. Biol. Reprod.71(3), 993–1001 (2004).
   Google Scholar
• Vingtdeux V, Hamdane M, Loyens A et al. Alkalizing drugs induce accumulation of amyloid precursor protein by-products in luminal vesicles of multivesicular bodies. J. Biol. Chem.282(25), 18197–18205 (2007).
   PubMedGoogle Scholar
• Liu J, Zhang JP, Shi M et al. Rab11a and HSP90 regulate recycling of extracellular α-synuclein. J. Neurosci.29(5), 1480–1485 (2009).
   PubMed Web of Science ®Google Scholar
• El-Agnaf OM, Salem SA, Paleologou KE et al. α-synuclein implicated in Parkinson’s disease is present in extracellular biological fluids, including human plasma. FASEB J.17(13), 1945–1947 (2003).
   PubMed Web of Science ®Google Scholar
• Lee SJ. Origins and effects of extracellular α-synuclein: implications in Parkinson’s disease. J. Mol. Neurosci.34(1), 17–22 (2008).
   PubMedGoogle Scholar
• Zhang J, Sokal I, Peskind ER et al. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am. J. Clin. Pathol.129(4), 526–529 (2008).
   PubMed Web of Science ®Google Scholar
• Shi M, Caudle WM, Zhang J. Biomarker discovery in neurodegenerative diseases: a proteomic approach. Neurobiol. Dis.35(2), 157–164 (2009).
   PubMed Web of Science ®Google Scholar
• Hollywood K, Brison DR, Goodacre R. Metabolomics: current technologies and future trends. Proteomics6(17), 4716–4723 (2006).
   PubMed Web of Science ®Google Scholar
• Issaq HJ, Van QN, Waybright TJ, Muschik GM, Veenstra TD. Analytical and statistical approaches to metabolomics research. J. Sep. Sci.32(13), 2183–2199 (2009).
   PubMed Web of Science ®Google Scholar
• Ascherio A, LeWitt PA, Xu K et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch. Neurol.66(12), 1460–1468 (2009).
   PubMed Web of Science ®Google Scholar
• Schwarzschild MA, Schwid SR, Marek K et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch. Neurol.65(6), 716–723 (2008).
   PubMed Web of Science ®Google Scholar
• Schlesinger I, Schlesinger N. Uric acid in Parkinson’s disease. Mov. Disord.23(12), 1653–1657 (2008).
   PubMed Web of Science ®Google Scholar
• Weisskopf MG, O’Reilly E, Chen H, Schwarzschild MA, Ascherio A. Plasma urate and risk of Parkinson’s disease. Am. J. Epidemiol.166(5), 561–567 (2007).
   PubMed Web of Science ®Google Scholar
• Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc. Natl Acad. Sci. USA78(11), 6858–6862 (1981).
   PubMed Web of Science ®Google Scholar
• Bogdanov M, Matson WR, Wang L et al. Metabolomic profiling to develop blood biomarkers for Parkinson’s disease. Brain131(Pt 2), 389–396 (2008).
   PubMed Web of Science ®Google Scholar
• Johansen KK, Wang L, Aasly JO et al. Metabolomic profiling in LRRK2-related Parkinson’s disease. PLoS One4(10), e7551 (2009).
   Web of Science ®Google Scholar